Follistatin-344 (FST-344): Complete Guide to Benefits, Dosing, and Research (2026)

Follistatin-344 (FST-344) is one of the most scientifically compelling peptides in the research community. As a natural myostatin inhibitor and activin antagonist, it can remove the body's built-in ceiling on muscle growth. Animal studies have shown muscle mass increases of up to 200% with follistatin gene delivery. Early human clinical trials in muscular dystrophy patients confirm functional improvement and a strong short-term safety profile. But FST-344 also carries unique risks — from a theoretical cancer link to documented eye complications from overdosing — and the evidence base for direct peptide injection in healthy humans simply doesn't exist.

What Is Follistatin-344?

Follistatin was first isolated in 1987 from porcine ovarian follicular fluid, initially identified as a substance capable of suppressing FSH secretion. It is an endogenous glycoprotein encoded by the FST gene. The FST gene produces multiple isoforms: FST-288 (cell-surface bound), FST-315 (primary circulating isoform), and FST-344 (the precursor that yields both). FST-344 is preferred in research because it retains a heparan sulfate-binding domain for local tissue retention while also producing circulating FST-315 — giving it dual local/systemic activity.

Mechanism: Myostatin Inhibition

Myostatin (GDF-8) acts as the body's natural brake on skeletal muscle growth by binding to ActRIIB receptors, triggering SMAD2/3 phosphorylation that suppresses muscle differentiation. FST-344 physically encircles myostatin at the molecular level, blocking its docking sites on ActRIIB. Beyond myostatin, FST-344 also neutralizes activin A and activin B — providing dual TGF-β inhibition that may offer superior muscle preservation over targeted myostatin inhibitors alone. When myostatin is neutralized, satellite cells proliferate freely and fuse into muscle fibers, driving hypertrophy and (in some animal models) hyperplasia.

The Research: Animal Studies and Human Trials

Animal data is striking: AAV-follistatin delivery produced muscle mass increases of up to 200% in mice. Rat studies showed a 24% increase in muscle mass and 42% increase in fiber cross-sectional area in just 17 days. A landmark 2009 nonhuman primate study demonstrated durable muscle size and strength increases with no organ pathology after AAV1-FS344 intramuscular injection.

Human clinical data — critically — comes from gene therapy, not peptide injection. In a Phase 1/2a trial in Becker Muscular Dystrophy (NCT01519349), 6 of 8 subjects showed increased muscle fiber diameter and functional improvement on the 6-minute walk test at 12 months, with no serious adverse events. A Phase 1/2 trial in inclusion body myositis showed annualized improvement of +56.0 m/year versus −25.8 m/year decline in controls (p=0.01).

Benefits

• Muscle hypertrophy: Removes myostatin's growth ceiling, enabling greater satellite cell recruitment and fiber enlargement
• Fat loss: Indirectly via increased muscle mass raising metabolic rate; directly via activin inhibition of adipogenesis
• Anti-aging/sarcopenia: Follistatin overexpression in aged animals reversed muscle mass decline and improved neuromuscular junction integrity
• Fertility modulation: Buffers activin-driven FSH regulation (though excessive FSH suppression can be counterproductive)
• Hair growth: Preliminary clinical data shows increased hair count and shaft thickness

Dosing Protocols

Disclaimer: These come from research communities, not FDA-approved protocols.

The plasma half-life is approximately 3–4 hours. At doses above 300 mcg/day, off-target activin and BMP pathway effects become more likely. Case reports document joint discomfort and mild testosterone suppression at doses exceeding 400 mcg/day.

FST-344 vs. Other Myostatin Inhibitors

vs. ACE-031: ACE-031 is an engineered decoy ActRIIB receptor. Its Phase 2 trials were halted due to vascular side effects (nosebleeds, telangiectasia) from broader BMP pathway inhibition. FST-344's endogenous binding profile may offer a better safety window.

vs. YK11: YK11 is a SARM that indirectly inhibits myostatin by upregulating follistatin expression. Unlike FST-344, it carries androgenic/hepatic risks associated with SARMs and has no clinical trial data.

Side Effects and Safety

• Joint/tendon stress: Rapid hypertrophy can outpace connective tissue adaptation. Stacking with BPC-157 or TB-500 is commonly recommended for this reason.
• Eye complications (CSCR): A 2020 case series documented 11 bodybuilders who developed central serous chorioretinopathy after injecting full 1 mg vials (~10x typical dose).
• Hormonal effects: Excessive FSH suppression via activin inhibition can disrupt testosterone regulation and fertility.
• Cancer risk (theoretical but serious): Activin acts as a growth suppressor in several cancers. Neutralizing it could theoretically remove tumor-suppressive signaling. A 2024 PMC review ("The Reign of Follistatin in Tumors") documents follistatin's complex pro-/anti-tumorigenic roles. Most researchers advise against FST-344 use in anyone with a personal or family history of cancer.
• Black market quality: A 2019 analysis found only 9 of 17 black market follistatin products actually contained follistatin — others contained MGF and GHRP-2.

Legal Status

FDA: Not approved for human use. Sold as a research chemical for laboratory use only.

WADA: Explicitly prohibited under Section S4.4 as an agent preventing ActRIIB activation. Ban covers all isoforms. WADA has funded detection studies specifically for black market FST-344.

Stacking

FST-344 + IGF-1 LR3: The most complementary pairing — FST-344 removes the growth brake while IGF-1 amplifies mTOR anabolic signaling. Additive muscle mass effects confirmed in research models.

FST-344 + BPC-157/TB-500: Recovery-focused. Addresses the joint/tendon stress side effect by supporting connective tissue adaptation.

FST-344 + CJC-1295/Ipamorelin: Non-overlapping mechanisms (TGF-β vs GH/IGF-1 axis) — theoretically additive, but compound complexity increases substantially.

Conclusion

Follistatin-344 occupies a unique position: no other peptide has demonstrated the magnitude of muscle growth seen in FST-344 animal studies, and the gene therapy human trials have produced genuinely positive functional outcomes with a favorable short-term safety profile. But FST-344 is not routine. The cancer risk is biologically plausible and serious. The eye complication case series demonstrates real-world overdose consequences. The legal landscape is unambiguous. For researchers evaluating FST-344, the animal and gene therapy evidence provides a strong scientific foundation — but controlled human trials for peptide injection in healthy subjects remain absent. The most compelling future applications are therapeutic: muscular dystrophy, sarcopenia, cachexia. That evidence is building steadily.

For educational purposes only. FST-344 is not FDA-approved for human use. Nothing in this article constitutes medical advice.